Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss

Transplantation. 1997 Nov 27;64(10):1493-6. doi: 10.1097/00007890-199711270-00024.

Abstract

Background: Although most transplanted patients with underlying IgA nephropathy (IgAN) develop histological recurrence, its clinical relevance is considered low.

Methods: We performed a single-center analysis of 61 renal transplant patients with IgAN.

Results: Forty-four percent of the patients showed a stable graft function. Progressive graft dysfunction apparently due to recurrent IgAN occurred in 23% of the patients (16% required dialysis). Five patients were retransplanted, and three again developed dialysis-dependent renal failure apparently due to recurrent IgAN. In 20% of the patients, chronic transplant dysfunction was due to other reasons, whereas no reason was identified in 13% of the patients. Neither findings before transplantation, the ACE genotype, the type of immunosuppression, nor the course after transplantation predicted transplant dysfunction due to recurrent IgAN. Follow-up after transplantation was longer in the group with dysfunction due to recurrent disease than in the group with dysfunction due to chronic rejection or in the stable group.

Conclusion: Recurrent IgAN is a clinically relevant problem in renal transplant patients. Its importance may have been underestimated in the past due to inadequate lengths of follow-up.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biopsy
  • Female
  • Genotype
  • Glomerulonephritis, IGA / immunology*
  • Graft Rejection / etiology
  • Humans
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / pathology
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / genetics
  • Polymorphism, Genetic
  • Recurrence

Substances

  • Peptidyl-Dipeptidase A